NL-OMON31329尚未招募2 期
Double blind, placebo controlled study Tacrolimus versus Emmolient in localized scleroderma - tacrolimus
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adults (aged ³ 18 years)
- •Patients must have a clinical diagnose of active morphea
- •Patients must have stopped systemic immunosuppressives/antifibrotic agents 3 months before start of this study
- •Wash out time for local treatments (like dermatocorticosteroids) is 3 weeks
排除标准
- •Prooved adverse reactions of protopic (tacrolimus) in the past (hypersensitivity/intolerance)
- •Females who are pregnant or nursing or planning to become pregnant
- •Recent treatment with (dermato) corticosteroids or other antifibrotic therapy
- •Active skin infection at the morpheaplaque
- •Recent vaccination (from 14 days before start of this study)
研究者
相似试验
已完成
不适用
A randomized controlled study of tacrolimus for the treatment of idiopathic membranous nephropathyIdiopathic membranous nephropathyUrological and Genital DiseasesISRCTN17977921The First Affiliated Hospital of Zhengzhou University (China)120
进行中（未招募）
1 期
A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy - SALAMIMabCampath / Alemtuzumab will be used as part of the immunosuppression regime following renal transplant.EUCTR2006-000830-11-GBeeds Teaching Hospitals NHS Trust120
已完成
2 期
A double blind placebo controlled clinical trial to evaluate the efficacy and safety of Shatavari in Menstrual irregularityCTRI/2011/06/001804The Himalaya Drug Company50
已完成
2 期
tamoxifen added to litihium in patint with acute maniaMania episode.Mania episodeIRCT1138901151556N12Tehran University of Medical Sciences40
招募中
2 期
to Evaluate Efficacy and Safety of Emotional discouragement capsules in Individuals presenting with mild occasional emotional discouragementCTRI/2018/05/013614The Himalaya Drug Company